Showing 2341-2350 of 8586 results for "".
Atopic Dermatitis: Understanding the Impact
https://practicaldermatology.com/topics/atopic-dermatitis/atopic-dermatitis-understanding-the-impact/19667/For most AD patients, eczema is a bumpy ride. Even mild cases of atopic dermatitis can have a significant effect on people—and these effects range from quality of life impact to treatment costs. Peter Lio, MD describes his approach to a long-term eczema management plan.DermWire TV: Focus on Skin Cancer Awareness
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwire-tv-focus-on-skin-cancer-awareness/19613/For skin cancer awareness month, the AAD rolls out a new campaign, urging the public to “Practice Safe Sun.” The Skin Cancer Foundation is 40! Founded in 1979, the foundation made its mark in 1983 when it introduced its seal for sunscreens. SCF President, Deborah Sarnoff, MD discusses the foundationCosmeceutical Options
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/cosmeceutical-options/18208/As the cosmeceutical market continues to grow, Nancy Samolitis, MD highlights one of her favorite options to support skin health.Cosmetic Boot Camp 2018 Presenter Insight
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/cosmetic-boot-camp-2018-presenter-insight/18290/Get up to date on Cosmetic Bootcamp. Presenters provide updates on microneedling, radiofrequency devices, lasers, fillers, neurotoxins, and more. The Cosmetic Bootcamp® provides training and educational opportunities for aesthetic medicine physicians and their staff. Hear from: Mary Lupo, MD; Vic NaSunscreen Ratings, Restylane Lyft for Hands, NPF, SCF News
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-sunscreen-ratings-restylane-lyft-for-hands-npf-scf-news/18305/Both Consumer Reports and the Environmental Working Group have issued sunscreen rankings, and while some products shine, many products may underperform. FDA issued warnings to several companies illegally marketing dietary supplements that make unproven drug claims about protecting consumers from sunEczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, andGalderma's Differin Goes OTC, CoolSculpting Approved for Upper Arms, ZO Skin Acquires ReFissa
https://practicaldermatology.com/series/dermwire-tv/galderma-s-differin-goes-otc-coolsculpting-approved-for-upper-arms-zo-skin-acquires-refissa/18549/Galderma's Differin Gel formulation of adapalene 0.1% is now available over the counter at major retail and drug stores in the US. ZELTIQ® Aesthetics' CoolSculpting is now FDA-cleared for fat reduction in the upper arms. ZO Skin Health has acquired the worldwide rights to ReFissa from Suneva MedicalHumphries to Valeant, Restylane Line Expands, 2016 Highlights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-humphries-to-valeant-restylane-line-expands-2016-highlights/18709/The filler market in the US expands with FDA approval of Galderma's Restylane Refyne and Restalyne Define for the treatment of nasolabial folds in patients over the age of 21. The gels are manufactured with XpresHAn Technology, which allows a range of flexibility and support for varied patient needsAubio Launches, Updates from Prescriber's Choice, BioPharmX
https://practicaldermatology.com/topics/practice-management/dermwiretv-aubio-launches-updates-from-prescriber-s-choice-biopharmx/18584/In this edition of DermWireTV, Aubio launches OTC treatment for cold sores with backing from Paul Mitchell partner. Prescriber's Choice facilitates in-office prescription dispensing. BioPharmX enrolls phase 2b trial for topical minocycline and Merz acquires ONLight Sciences, maker of PFD patch for tTarget: PASI 90
https://practicaldermatology.com/topics/psoriasis/target-pasi-90/18593/With new advancements in biologic therapy, patients are gaining more control of psoriasis. Whereas PASI 50 was once seen as a significant improvement, patients today can expect to achieve PASI 90. Can PASI 100 be far behind?